In a landmark achievement for transplant medicine, surgeons at UChicago Medicine have successfully performed a quadruple-organ transplant on a 28-year-old patient suffering from the advanced, systemic complications of cystic fibrosis (CF). The procedure—the first of its kind in Illinois and only the sixth in the history of the United States—represents a triumph of multidisciplinary surgical coordination and a beacon of hope for patients with multisystem organ failure.
The recipient, Jasmine Jones, endured a grueling 36-hour operation that saw the replacement of her lungs, liver, and kidney. By removing the primary source of chronic infection while simultaneously addressing end-stage organ failure, the surgical team was able to provide Jones with a clean slate, effectively curing the systemic manifestations of her condition.
Key Takeaways
- Unprecedented Scope: This marks the first quadruple-organ transplant in Illinois and only the sixth in the United States, as recorded by the United Network for Organ Sharing (UNOS).
- Strategic Intervention: Surgeons opted for a simultaneous approach to address drug-resistant bacteria in the lungs that threatened the viability of the liver and kidney transplants.
- Multidisciplinary Triumph: The surgery highlights the unique capabilities of the UChicago Medicine Transplant Institute, which maintains a global reputation for managing high-complexity, multi-organ cases.
The Clinical Journey: A Chronology of Care
Jasmine Jones’s history with cystic fibrosis began in infancy. While she navigated a relatively typical childhood, the genetic nature of the disease meant that as she matured, the accumulation of thick, viscous mucus began to wreak havoc on her body’s vital systems. By her late teens, the clinical picture had darkened significantly. Chronic respiratory infections led to permanent lung scarring, while the systemic nature of CF caused the ducts in her liver to become obstructed by thick bile, leading to secondary failure in both the liver and kidneys. Furthermore, she developed CF-related diabetes, complicating her metabolic profile.
The Turning Point
By late 2025, the standard of care for CF—specifically cystic fibrosis transmembrane conductance regulator (CFTR) modulators—was no longer an option for Jones, as she was unable to tolerate the medication. Her condition plummeted, necessitating a desperate need for a liver and kidney transplant. However, a massive clinical hurdle remained: Jones’s diseased lungs harbored drug-resistant bacteria.
The medical team faced a catch-22. If they performed the liver and kidney transplants while leaving her compromised lungs in place, the immunosuppression required to prevent organ rejection would likely allow the pulmonary bacteria to trigger a lethal systemic infection.
The Operation: January 5, 2026
The surgical intervention was meticulously planned as a staged, yet integrated, process.
- Phase 1: Pulmonary Replacement. Surgeons began by removing both of Jones’s lungs and replacing them with healthy donor organs. This was the critical first step to eliminate the "bacterial reservoir."
- Phase 2: Hepatic Implantation. Following the lung transplant, the surgical team moved to replace her failing liver. To ensure the health of the donor organ, they utilized a specialized perfusion device that continuously pumped oxygenated, nutrient-rich blood through the liver, keeping it in peak condition before integration.
- Phase 3: Renal Implantation. After a critical 24-hour monitoring period in the Intensive Care Unit (ICU), the team completed the final stage of the procedure: the implantation of a donor kidney.
Following the surgery, Jones remained in the hospital for six weeks of stabilization, followed by an intensive inpatient rehabilitation program to regain her strength.
Supporting Data: Why This Procedure Was Necessary
Cystic Fibrosis is fundamentally a disease of protein transport. The CFTR protein, which regulates the flow of salt and fluids in and out of cells, is dysfunctional in patients with CF. This leads to the production of mucus that is 30 to 60 times thicker than normal.
The Multisystem Impact
The data regarding CF-related organ failure is stark. As pulmonologist Dr. Edward Naureckas explained, the liver in CF patients is particularly vulnerable. "The liver secretes bile through very small ducts, and these ducts get plugged up because the bile is too thick," Dr. Naureckas noted. "This creates a chain reaction of inflammation and fibrosis that eventually leads to cirrhosis."
When this is paired with pulmonary failure, the patient’s physiological reserves are almost entirely depleted. For patients like Jones, the "triple-threat" of lung, liver, and kidney failure creates a surgical landscape where traditional transplant protocols are insufficient. The decision to perform a quadruple transplant was not made lightly; it was a calculated risk aimed at preventing post-operative sepsis.
The Role of Technology
The use of mechanical perfusion for the donor liver was a decisive factor in the operation’s success. By maintaining the organ in an ex-vivo state with oxygenated blood, the team mitigated "ischemia-reperfusion injury," a common complication where tissue damage occurs when blood supply returns to an organ after a period of ischemia.
Official Responses and Medical Expertise
The success of the operation has been attributed to the unique culture of collaboration at UChicago Medicine. The institution is widely regarded as a world leader in triple-organ transplants, having developed a logistical framework that allows for the synchronization of massive surgical teams.
"It’s second nature at UChicago Medicine to work in big teams and across medical specialties," said Dr. Rolf Barth, transplant surgeon and co-director of the UChicago Medicine Transplant Institute. "The number of people involved in Jasmine’s case—from the initial work-up to the ethics committee approval, the procurement, and the surgery itself—is a level of coordination that even top-tier centers often cannot replicate."
Dr. Pablo Sanchez, the thoracic surgeon who led the lung replacement portion of the surgery, emphasized the necessity of the "total replacement" strategy. "We needed to remove both lungs to eliminate the probability of that hard-to-treat bacteria creating catastrophic problems later," Dr. Sanchez said. "If we hadn’t addressed the lungs, the immunosuppression required for the liver and kidney would have effectively cleared the path for a lethal infection."
The surgical team also praised the resilience of the patient. Dr. Ashley Suah, who managed the kidney and liver aspects of the surgery, noted, "Jasmine’s body had been through so much, but she handled every challenge incredibly well. Her recovery is a testament to both her personal fortitude and the precision of our surgical protocols."
Implications for the Future of Transplant Medicine
The successful case of Jasmine Jones serves as a "proof of concept" for treating patients with advanced, multi-organ CF complications.
Expanding the Donor Pool and Surgical Horizons
While CFTR modulators have revolutionized the treatment of cystic fibrosis, they are not a panacea for all patients. For those who are intolerant to these drugs or who have already progressed to irreversible end-stage organ damage, the UChicago model provides a new pathway. It demonstrates that with the right combination of organ perfusion technology, aggressive infection management, and multi-specialty surgical teams, "inoperable" patients can indeed be saved.
The Path Forward
Jones is currently undergoing regular outpatient care and strict adherence to an immunosuppressant regimen to prevent organ rejection. Her new organs are showing no signs of CF, as the genetic defect is localized to the cells of the host, not the donor organs.
As of early 2026, the medical community is closely monitoring Jones’s progress. Her case is expected to influence clinical guidelines for how transplant centers approach "complex-comorbidity" patients. By proving that a quadruple-organ transplant is a viable, life-saving option, UChicago Medicine has effectively raised the ceiling for what is possible in modern transplant surgery.
For patients living with the severe, multisystem realities of cystic fibrosis, this outcome offers more than just clinical data—it offers a template for survival where previously there was only the prospect of palliative care. The success of this 36-hour window in January serves as a monumental reminder of the progress being made at the intersection of genetic understanding and surgical innovation.
